| Sign In to gain access to subscriptions and/or personal tools. |
The pharmacological potency of various AT1 antagonists assessed by Schild regression technique in manCentre for Cardiovascular Pharmacology, ZeKaPha GmbH, Mainz, Germany
Centre for Cardiovascular Pharmacology, ZeKaPha GmbH, Mainz, Germany
Centre for Cardiovascular Pharmacology, ZeKaPha GmbH, Mainz, Germany
Takeda Pharma GmbH, Aachen, Germany
Centre for Cardiovascular Pharmacology, ZeKaPha GmbH, Mainz, Germany
Centre for Cardiovascular Pharmacology, ZeKaPha GmbH, Mainz, Germany Rationale A quantitative technique was used to compare the pharmacological potency in healthy volunteers of angiotensin II receptor antagonists (AIIA): candesartan cilexetil, losartan, irbesartan, valsartan, and telmisartan. Methods In a randomised, double-blind, parallel-group (4x12 subjects) study, single oral doses of candesartan cilexetil 4, 8 and 16 mg, losartan potassium 25, 50 and 100 mg, valsartan 40, 80 and 160 mg, and irbesartan 75, 150 and 300 mg were administered on three consecutive days. Telmisartan 20, 40 and 80 mg was similarly evaluated in 12 volunteers in an open amendment. Angiotensin II (Ang II) antagonistic effects were determined in vivo from rightward shifts in Ang II dose-response curves for diastolic blood pressure (BP) and dose ratios were calculated. Apparent Ki-doses, i.e. doses (in mg) required to induce a two-fold shift in Ang II dose-response curves (equivalent to approx. 50% blockade of receptors) were determined, using Schild regression analysis. Results All treatments dose-dependently attenuated increases in diastolic BP induced by infusion of exogenous Ang II. Candesartan cilexetil appeared to have a more pronounced increase in effect following cumulative dosing. At 24 hours, apparent K i-doses were: candesartan cilexetil 6 mg, irbesartan 123 mg, valsartan 93.5 mg, and telmisartan 54 mg. It was not possible to determine an apparent Ki-dose for losartan at 24 hours. Conclusion Consistent with results from experimental pharmacology, candesartan cilexetil displayed the highest pharmacological potency (i.e. antagonistic activity per mg substance) of the AIIAs tested. Apparent Ki-doses at 24 hours were within the dose range recommended for clinical use in patients with hypertension.
Key Words: angiotensin II antagonists • dose ratio • Schild regression technique • candesartan • irbesartan • losartan • telmisartan • valsartan
Journal of Renin-Angiotensin-Aldosterone System, Vol. 1, No. 4,
336-341 (2000) |
|||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
